Evidence & regulatory context
- Mechanism
- Not recorded
- Target
- Not recorded
- Injury models
- Chemical/toxin
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 1
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Randomized, Placebo-Controlled, Double-blind, Dose-Ranging, Multicenter Phase IIb Trial of allo-APZ2-CVU (allogeneic ABCB5-positive dermal mesenchymal stromal cells) on Wound Healing of Therapy-Resistant Chronic Venous Ulcer
Skin Ulcer Venous Stasis Chronic
Enrolment: 159 · Results not recorded
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
MouseChemical/toxinC57BL/6J recipients; EGFP-transgenic CByJ.B6-Tg(CAG-EGFP)1Osb/J donorsMale recipients; donor sex not statedHepatic portal vein (fibrosis model); tail vein (irradiation model)Week 6 of a 10 week CCl4 regimen; 4 h after 8 Gy total-body irradiation
Model: CCl4-induced liver fibrosis (0.6 ml/kg intraperitoneally twice weekly for 10 weeks) and 8 Gy lethal total-body irradiation
DMCs transplantation reduced CCl4-induced fibrosis and restored liver function, and improved survival after 8 Gy total-body irradiation, with long-term hepatic engraftment of a macrophage-like DMC population.
Extraction: extract · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.
